SIRT6: therapeutic target for nonalcoholic fatty liver disease

Trends Endocrinol Metab. 2022 Dec;33(12):801-803. doi: 10.1016/j.tem.2022.10.004. Epub 2022 Nov 1.

Abstract

Recently, Hou et al. shifted the research focus from the function of nuclear sirtuin (SIRT)6 to that of cytoplasmic SIRT6, which deacetylates and activates long-chain acyl-CoA synthase 5 (ACSL5). Their findings provide mechanistic insight into the role of cytoplasmic SIRT6 in fatty acid oxidation, acting as a therapeutic target for combating nonalcoholic fatty liver disease (NAFLD).

Keywords: SIRT6; deacetylation; fatty acid oxidation; lipid metabolism; long-chain acyl-CoA synthase 5; nonalcoholic fatty liver disease.

Publication types

  • Research Support, N.I.H., Extramural
  • Research Support, N.I.H., Intramural
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Fatty Acids / metabolism
  • Humans
  • Lipid Metabolism
  • Liver / metabolism
  • Non-alcoholic Fatty Liver Disease* / drug therapy
  • Non-alcoholic Fatty Liver Disease* / metabolism
  • Sirtuins* / metabolism

Substances

  • Fatty Acids
  • Sirtuins
  • SIRT6 protein, human